Literature DB >> 8553544

Genetic determinants of feline leukemia virus-induced multicentric lymphomas.

G B Athas1, B Choi, S Prabhu, P A Lobelle-Rich, L S Levy.   

Abstract

Three discrete forms of feline leukemia virus (FeLV)-associated lymphoma have been described clinically: (1) thymic, (2) alimentary, and (3) multicentric. The most common and best-characterized lymphomas are of T-cell origin, generally occurring in the thymus. These tumors typically contain mature T-cells, involve the activation of a distinctive set of proto-oncogenes, and contain FeLV proviruses whose long terminal repeat (LTR) sequences contain tandemly repeated enhancers. Previous studies of a small group of extrathymic, multicentric lymphomas implicated a different set of genetic determinants. The present study expands those observations by examining the lineage of origin, the involvement of proto-oncogenes, and the structure of LTR and env gene sequences in a set of 11 natural, extrathymic lymphomas of the multicentric type. A pattern of genetic events associated with FeLV-positive multicentric lymphomas emerges from this analysis that is clearly distinct from the pattern associated with thymic lymphomas. The tumors do not contain T-cells or B-cells, as evidenced by the germ line organization of TCR beta and IgH loci. Proto-oncogenes strongly implicated in T-cell lymphomagenesis are not involved in these tumors. Rather, a distinct set of proto-oncogenes may be involved. Most striking is the repeated occurrence of an FeLV isolate whose LTR and env gene bear unique sequence elements.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8553544     DOI: 10.1006/viro.1995.0053

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  21 in total

1.  Selection of reversions and suppressors of a mutation in the CBF binding site of a lymphomagenic retrovirus.

Authors:  M J Martiney; K Rulli; R Beaty; L S Levy; J Lenz
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

2.  Tissue distribution and timing of appearance of polytropic envelope recombinants during infection with SL3-3 murine leukemia virus or its weakly pathogenic SL3DeltaMyb5 mutant.

Authors:  K Rulli; P A Lobelle-Rich; A Trubetskoy; J Lenz; L S Levy
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

3.  Seroprevalence of feline immunodeficiency virus (FIV) and feline leukemia virus (FeLV) in shelter cats on the island of Newfoundland, Canada.

Authors:  Hannah J Munro; Lesley Berghuis; Andrew S Lang; Laura Rogers; Hugh Whitney
Journal:  Can J Vet Res       Date:  2014-04       Impact factor: 1.310

4.  Subtle mutational changes in the SU protein of a natural feline leukemia virus subgroup A isolate alter disease spectrum.

Authors:  Chandtip Chandhasin; Patricia N Coan; Laura S Levy
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

5.  The feline leukemia virus long terminal repeat contains a potent genetic determinant of T-cell lymphomagenicity.

Authors:  J Pantginis; R M Beaty; L S Levy; J Lenz
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

6.  The surface glycoprotein of a natural feline leukemia virus subgroup A variant, FeLV-945, as a determinant of disease outcome.

Authors:  Lisa L Bolin; Shamim Ahmad; Laura S Levy
Journal:  Vet Immunol Immunopathol       Date:  2011-06-12       Impact factor: 2.046

7.  The surface glycoprotein of feline leukemia virus isolate FeLV-945 is a determinant of altered pathogenesis in the presence or absence of the unique viral long terminal repeat.

Authors:  Lisa L Bolin; Shamim Ahmad; Patricia A Lobelle-Rich; Tara G Ooms; Xavier Alvarez-Hernandez; Peter J Didier; Laura S Levy
Journal:  J Virol       Date:  2013-07-31       Impact factor: 5.103

8.  Unique long terminal repeat and surface glycoprotein gene sequences of feline leukemia virus as determinants of disease outcome.

Authors:  Chandtip Chandhasin; Patricia N Coan; Ivona Pandrea; Chris K Grant; Patricia A Lobelle-Rich; Adriane Puetter; Laura S Levy
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

Review 9.  Advances in understanding molecular determinants in FeLV pathology.

Authors:  Laura S Levy
Journal:  Vet Immunol Immunopathol       Date:  2008-01-19       Impact factor: 2.046

10.  Suppressor mutations within the core binding factor (CBF/AML1) binding site of a T-cell lymphomagenic retrovirus.

Authors:  M J Martiney; L S Levy; J Lenz
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.